Aligos Therapeutics, Inc. (ALGS) cash on hand
Aligos Therapeutics, Inc. (ALGS) held cash of $77.84M at the end of fiscal 2025 (December 31, 2025). That is 36.7% higher than the $56.94M of fiscal 2024. Figures as of 17 Nov 2026, 22:26 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Cash, fiscal 2025
- $77.84M
- Change on fiscal 2024
- +36.7%
- Highest on record
- $135.70Mfiscal 2023
- Lowest on record
- $56.94Mfiscal 2024
- Fiscal years on record
- 42022–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Aligos Therapeutics, Inc. cash on hand, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $135.70M in fiscal 2023 and the lowest $56.94M in fiscal 2024.
Cash by fiscal year
Aligos Therapeutics, Inc. cash on hand, year by year
| Fiscal year | Cash | Change | Year ended |
|---|---|---|---|
| 2025 | $77.84M | 36.7% up | |
| 2024 | $56.94M | 58.0% down | |
| 2023 | $135.70M | 7.8% up | |
| 2022 | $125.83M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
How to read it
Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.
Aligos Therapeutics, Inc., figure by figure
- Aligos Therapeutics, Inc. market cap
- Aligos Therapeutics, Inc. revenue
- Aligos Therapeutics, Inc. earnings
- Aligos Therapeutics, Inc. earnings per share (EPS)
- Aligos Therapeutics, Inc. P/E ratio
- Aligos Therapeutics, Inc. P/S ratio
- Aligos Therapeutics, Inc. P/B ratio
- Aligos Therapeutics, Inc. free cash flow
- Aligos Therapeutics, Inc. operating margin
- Aligos Therapeutics, Inc. dividend
- Aligos Therapeutics, Inc. shares outstanding
- Aligos Therapeutics, Inc. total debt
- Aligos Therapeutics, Inc. total assets
- Aligos Therapeutics, Inc. return on equity (ROE)
- Aligos Therapeutics, Inc. return on invested capital (ROIC)
Aligos Therapeutics, Inc. (ALGS) overview: price, valuation and scorecard
Aligos Therapeutics, Inc. cash on hand: questions and answers
How much cash does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. (ALGS) held cash of $77.84M at the end of fiscal 2025 (December 31, 2025). That is 36.7% higher than the $56.94M of fiscal 2024.
What are the highest and lowest cash figures on record for Aligos Therapeutics, Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $135.70M in fiscal 2023 and the lowest $56.94M in fiscal 2024.
How is Aligos Therapeutics, Inc.'s cash calculated?
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
Fiscal years are named for the calendar year they end in.
Learn: cash on hand
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Aligos Therapeutics, Inc. (ALGS) cash on hand”, data as of 17 November 2026. https://funkfolio.com/stock/ALGS/cash
Underlying data: the company's filings with the SEC and Yahoo Finance.